|
1
|
Michot J, Carpio C, Nastoupil L, Chavez J, Feldman T, Ferrari S, Morillo D, Bachy E, Pinto A, Kuruvilla J, Buchholz TJ, Kasibhatla S, Carrancio S, Guarinos C, Wu F, Li S, Patah P, Pourdehnad M. A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS. Hematol Oncol 2021. [DOI: 10.1002/hon.89_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- J.‐M. Michot
- Gustave Roussy Institute of Cancer Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP) Villejuif France
| | - C. Carpio
- Vall d'Hebron Institute of Oncology (VHIO) University Hospital Vall d'Hebron University Autònoma of Barcelona (UAB) Department of Hematology Barcelona Spain
| | - L. Nastoupil
- MD Anderson Cancer Center University of Texas Department of Lymphoma & Myeloma Houston Texas USA
| | - J. Chavez
- Moffitt Cancer Center University of South Florida Department of Malignant Hematology Tampa Florida USA
| | - T. Feldman
- Hackensack Meridian Health Lymphoma Division Edison New Jersey USA
| | - S. Ferrari
- Papa Giovanni XXIII Hospital Dipartimento di Ematologia Bergamo Italy
| | - D. Morillo
- Hospital Fundación Jiménez Díaz Department of Hematology Madrid Spain
| | - E. Bachy
- Hospices Civils de Lyon Department of Hematology Lyon France
| | - A. Pinto
- National Cancer Institute Fondazione G. Pascale IRCCS Hematology‐Oncology & Stem Cell Transplantation Unit Napoli Italy
| | - J. Kuruvilla
- Princess Margaret Cancer Centre Cancer Clinical Research Unit Division of Medical Oncology and Hematology Toronto Canada
| | - T. J. Buchholz
- Bristol Myers Squibb Early Clinical Development Oncology Princeton New Jersey USA
| | - S. Kasibhatla
- Bristol Myers Squibb Translational Biology Oncogenesis Therapeutic Research Center Princeton New Jersey USA
| | - S. Carrancio
- Bristol Myers Squibb Translational Biology Oncogenesis Therapeutic Research Center Princeton New Jersey USA
| | - C. Guarinos
- Bristol Myers Squibb ONC‐TRC CITRE Princeton New Jersey USA
| | - F. Wu
- Bristol Myers Squibb Clinical Pharmacology Early Clinical Development Princeton New Jersey USA
| | - S. Li
- Bristol Myers Squibb Global Biometric Sciences Princeton New Jersey USA
| | - P. Patah
- Bristol Myers Squibb Early Clinical Development Hematology/Oncology and Cell Therapy Princeton New Jersey USA
| | - M. Pourdehnad
- Bristol Myers Squibb Early Clinical Development Hematology/Oncology and Cell Therapy Princeton New Jersey USA
| |
Collapse
|
|
2
|
Guarinos C, Castillejo A, Barberá V, Carbonell L, Sanchez-Heras A, Castillejo M, Jover R, Paya A, Alenda C, Soto J. 171 Impact of TACSTD1 germline deletions as Lynch syndrome causing mutations in Spanish hereditary non-polyposis colorectal cancer – suspected patients. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70978-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|